Biparatopic anti-AXL ADC

Biparatopic anti-AXL ADC refers to a class of antibody-drug conjugates (ADCs) designed to target two distinct, non-overlapping epitopes on the AXL receptor tyrosine kinase. This biparatopic targeting strategy is engineered to promote receptor clustering, rapid internalization, and lysosomal trafficking, thereby enhancing the intracellular delivery and cytotoxic potency of the conjugated payload. Developed preclinically by organizations such as the National Research Council of Canada, these constructs often utilize single-domain antibodies (sdAbs/VHH) or monoclonal antibodies conjugated to microtubule-disrupting agents like maytansine (DM1) or other cytotoxic payloads. AXL is widely overexpressed in various cancers (including breast, lung, and ovarian cancers) and is associated with epithelial-to-mesenchymal transition, metastasis, and resistance to chemotherapy, making it a highly promising therapeutic target.

Other names

biparatopic anti-AXL antibody-drug conjugatebiparatopic Axl-DM1 ADC